Stathmin 1 Expression in Prostate Cancer
Author Information
Author(s): Shi Yingli, Yeh Yunshin A., Cheng Siyuan, Gu Xin, Yang Shu, Li Lin, Khater Nazih P., Kasper Susan, Yu Xiuping
Hypothesis
The study investigates the role of stathmin 1 (STMN1) expression in prostate cancer and its correlation with clinical outcomes.
Conclusion
The study found that elevated STMN1 expression is associated with poor clinical outcomes in prostate cancer patients and may serve as a diagnostic and prognostic marker.
Supporting Evidence
- Elevated STMN1 expression correlates with high Gleason Score and poor clinical outcomes in prostate cancer patients.
- STMN1 expression is positively correlated with the cell proliferation marker Ki67.
- Significant increase in STMN1 expression was observed in neuroendocrine prostate cancer compared to prostate adenocarcinoma.
- Elevated STMN1 expression was detected in TRAMP tumors, a mouse model of prostate cancer.
Takeaway
This study shows that a protein called stathmin 1 is found in higher amounts in aggressive prostate cancer, which could help doctors figure out how serious the cancer is.
Methodology
The study used bioinformatics analysis, western blotting, and immunohistochemical staining to analyze STMN1 expression in prostate cancer cell lines and tissue samples.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website